

Technology Available for Industry-Academia Collaboration or Technology Licensing.

“DBPR807: A CXCR4-Targeted Antagonist”

Date: 2022.7.26

1. Title:
NHRI technology, **“DBPR807: A CXCR4-Targeted Antagonist”**
(abbreviated as **“The Technology”**) available for industry-academia
collaboration or technology licensing.
2. Description:
3. DBPR807 is a small molecule CXCR4 antagonist. DBPR807 can significantly suppress tumor growth of hepatocellular carcinoma via reducing angiogenesis, normalizing tumor microenvironment, and promoting cytotoxic T cell infiltration. On the other hand, the rat and mini-pig animal studies demonstrated that DBPR807 possesses anti-inflammatory activity and can be used in acute myocardial infarction.
4. Potential collaboration partner qualifications:
 - (1) be incorporated and approved by law and does not have any record of misconduct or conviction for any offense
 - (2) better to have related experience and skills for developing **The Technology**
 - (3) better to have experience of international collaboration and clinical trial
 - (4) be willing to provide long-term investment
5. Registration :
Please contact to Ms. Wan-Ping Hsieh (email: wanping@nhri.edu.tw) or Ms. Wen-Chuan Hsieh (email: wenchuan@nhri.edu.tw). Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan.
6. Other:
 - (1) If **The Technology** has been exclusively licensed, this announcement will automatically invalid.
 - (2) NHRI retains the right to modify and terminate this announcement.
 - (3) For detailed status of **The Technology**, please contact to the case officer.

Attachments:

I: Announcement

II: Technology Transfer Vendor Qualification Form

III: Industry-Academia Collaboration Proposal